Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer

PURPOSE: To determine the effects of bevacizumab on patient-reported outcomes (PROs; secondary end point) in the AURELIA trial. PATIENTS AND METHODS: Patients with platinum-resistant ovarian cancer were randomly assigned to chemotherapy alone (CT) or with bevacizumab (BEV-CT). PROs were assessed usi...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Clin Oncol
Main Authors: Stockler, Martin R., Hilpert, Felix, Friedlander, Michael, King, Madeleine T., Wenzel, Lari, Lee, Chee Khoon, Joly, Florence, de Gregorio, Nikolaus, Arranz, José Angel, Mirza, Mansoor Raza, Sorio, Roberto, Freudensprung, Ulrich, Sneller, Vesna, Hales, Gill, Pujade-Lauraine, Eric
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Clinical Oncology 2014
נושאים:
ORIGINAL REPORTS
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4876313/
https://ncbi.nlm.nih.gov/pubmed/24687829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.51.4240
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים